They got into a research license agreement with Janssen (Johnson&Johnson) in April for an undisclosed target. Most likely for a type of cancer.
They recently announced several neutralizing SARS-cov-2 antibodies from their human and llama campaign. They will be soon announcing their antibodies discovered on Ligand’s (LGND) OmniAb platform (OmniRat) and also Rabbit antibodies. They’ll have 1600 Covid neutralizing mAbs.
In 2019 they created Talem Therapeutics which gives them the ability to out license their antibodies and partner with Big Pharma or whoever wants them. They already do business with several of big pharmas so the connections and trust are already there. When companies want to use IPAs services the audit process is roughly a year long so the Big Pharmas that are already on board should be very interested in their Covid discoveries.
They collaborated with the NIH for characterization of their antibodies. That should be released in a peer reviewed article in the near future. That will be big news and provide validation to the companies interested in licensing with them.
I don’t think there’s another company with the amount of sars-cov-2 specific antibodies like IPA. They did everything from the ground up and discovered mAbs from Humans, Llamas, Rabbits and OmniRat.
Will be interesting to see what moves they make this summer. They have potential to do several licensing deals (upfront payment+royalties) and also take an antibody cocktail through animal trials themselves.
IPA is also developing a saliva based test with the University of Victoria. A photographer from Bloomberg was there the other day so we should see some media coverage soon.
They also announced a Covid vaccine program that’s being funded by TRANSVAC in Europe. You only get that if your antibodies are good.
There’s so much going on with this company right now so we should be getting a lot of news soon. I’m sure their strategy is to bring in as many licensing deals (upfront payments) as possible which will set them up for future projects in immuno-oncology.
Few more developments and we should be headed to the Nasdaq where the real fun will start.
News 
Market Data 
Discover 
